2 Information about idelalisib

2 Information about idelalisib

Information about idelalisib

Marketing authorisation indication

Idelalisib (Zydelig, Gilead) has a marketing authorisation 'as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment'.

Dosage in the marketing authorisation

Idelalisib is administered orally at a dose of 150 mg, twice daily. Treatment is continued until disease progression or unacceptable toxicity.


The list price for idelalisib is £3,114.75 per pack of 60 x 150 mg film-coated tablets (excluding VAT, company submission).

The company has a commercial arrangement for idelalisib, which would apply if the technology had been recommended.

  • National Institute for Health and Care Excellence (NICE)